– UK, Oxford – Oxford, UK – Oxford Biomedica (LON: OXB), a leading gene and cell therapy group, today announced the appointment of Dr. Frank Mathias to its Board of Directors as CEO, effective on Monday, 27th March 2023.
“We are extremely excited about the imminent arrival of Frank as our new CEO. Frank brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica and I feel, with Frank’s new leadership, we are extremely well-positioned to deliver the growth and full potential of the company given our leading technology. As a viral vector leader, Oxford Biomedica is poised to build its position as a world-class, innovation-led CDMO delivering life-changing therapies to patients.” said Board Chair and interim CEO, Dr. Roch Doliveux.
The company also announced that effective on 27th March 2023, Stuart Henderson will become Vice-Chair while Professor Kay Davies will assume the role of Senior Independent Director.
About Dr. Frank Mathias
Dr. Mathias joins Oxford Biomedica from Rentschler Biopharma SE where he has been CEO since 2016. He successfully transformed Rentschler into a leading global, full-service CDMO and changed the financials of the business including a three-fold increase in revenue, while also improving efficiencies and profitability at an even faster rate.
Dr. Frank Mathias said: “I look forward to joining Oxford Biomedica and leading the Company in its mission to deliver innovative services to biopharma customers, enabling them to discover and deliver therapies that transform patients’ lives. Oxford Biomedica has a clear vision for the future, and I believe it has great potential to become the leader in the viral vector CDMO market. I firmly believe in the Company’s strategy for growth and am excited to start working towards our goal to deliver products to patients as quickly as possible.”
About Oxford Biomedica
Oxford Biomedica is an innovative leading viral vector specialist focused on delivering life-changing therapies to patients.
Oxford Biomedica plc and its subsidiaries work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus, and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development, and manufacturing needs. Oxford Biomedica has built a sector-leading lentiviral vector delivery system, the LentiVector platform, and is working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US-based subsidiary AAV manufacturing and innovation business, based near Boston, US.
For more information: https://www.oxfordbiomedica.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
